Interaction of dexmedetomidine combined with sufentanil in the treatment of adenomyopathy by high-intensity focused ultrasound

Objective To explore the interaction and compatibility optimization of dexmedetomidine combined with sufentanil in treatment of adenomyosis by high-intensity focused ultrasound (HIFU). Methods A total of 96 patients with adenomyosis who underwent HIFU treatment in Affiliated Hospital of Shandong Second Medical University from January 2023 to December 2023 were selected as the study subjects, and were randomly divided into 12 groups, with 8 cases in each group. The pain relief score (VAS score) and sedation score (Ramsay score) of the patient were recorded before surgery, 30 minutes after surgery began, and immediately after surgery. The changes of patients’ heart rate (HR), mean arterial pressure (MAP) and saturation of peripheral oxygen (SpO2) were monitored. The isobolographic analysis method was used to analyze the interaction between the two drugs at bispectral index for half of the patients falling asleep (BIS50). The response curve model was used to analyze the interaction law and optimal compatibility concentration range between dexmedetomidine and sufentanil, with the goal of 95% patients being satisfied with analgesia and Ramsay being effective in sedation. Results The response curve model showed that dexmedetomidine and sufentanil had a synergistic effect in the HIFU treatment of adenomyosis. When sufentanil concentration was 0.30, 0.40 and 0.45 μg/kg respectively, the optimal concentration range of dexmedetomidine was 0.53 to 0.65, 0.48 to 0.60 and 0.44 to 0.57 μg/kg respectively. Conclusion Dexmedetomidine and sufentanil have a synergistic effect on analgesia, and when used within the optimal compatibility concentration range, it can not only effectively relieve analgesia, but also reduce the occurrence of adverse reactions.